| Drug General Information |
| Drug ID |
D00UET
|
| Former ID |
DIB004208
|
| Drug Name |
SAR-407899
|
| Synonyms |
ROCK inhibitors, sanofi-aventis; Rho kinase inhibitors, sanofi-aventis
|
| Indication |
Diabetic nephropathy [ICD9: 250.4; ICD10:E11.21]
|
Phase 2 |
[1]
|
|---|
| Company |
Sanofi
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Rho-associated protein kinase 1 |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Chemokine signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Vascular smooth muscle contraction
|
|
TGF-beta signaling pathway
|
|
Axon guidance
|
|
Focal adhesion
|
|
Platelet activation
|
|
Leukocyte transendothelial migration
|
|
Regulation of actin cytoskeleton
|
|
Oxytocin signaling pathway
|
|
Pathogenic Escherichia coli infection
|
|
Shigellosis
|
|
Salmonella infection
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
PANTHER Pathway
|
Cytoskeletal regulation by Rho GTPase
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Signaling events mediated by PRL
|
|
RhoA signaling pathway
|
|
Noncanonical Wnt signaling pathway
|
|
EPHB forward signaling
|
|
Thromboxane A2 receptor signaling
|
|
PAR4-mediated thrombin signaling events
|
|
amb2 Integrin signaling
|
|
Integrins in angiogenesis
|
|
EPHA forward signaling
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
PAR1-mediated thrombin signaling events
|
|
N-cadherin signaling events
|
|
Reactome
|
Apoptotic cleavage of cellular proteins
|
|
EPHB-mediated forward signaling
|
|
EPHA-mediated growth cone collapse
|
|
G alpha (12/13) signalling events
|
|
Sema4D induced cell migration and growth-cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
RHO GTPases Activate ROCKs
|
|
WikiPathways
|
G13 Signaling Pathway
|
|
Regulation of Actin Cytoskeleton
|
|
EGF/EGFR Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
Focal Adhesion
|
|
JAK/STAT
|
|
AGE/RAGE pathway
|
|
Pathogenic Escherichia coli infection
|
|
Regulation of Microtubule Cytoskeleton
|
|
Leptin signaling pathway
|
|
Semaphorin interactions
|
|
Integrin-mediated Cell Adhesion
|
|
GPCR downstream signaling
|
|
Apoptotic execution phase
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Androgen receptor signaling pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00914277) SAR407899 Single-dose in Treatment of Mild to Moderate Erectile Dysfunction. U.S. National Institutes of Health. |
|---|
| REF 2 | The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012 May;30(5):980-9. |
|---|
